Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. (Q40481125)

20 September 2017

Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. (English)

1 reference

20 September 2017

1 reference

Marjorie Robert-Guroff

12

object named as

Marjorie Robert-Guroff

1 reference

20 September 2017

V Raúl Gómez-Román

1

1 reference

20 September 2017

George J Grimes

2

1 reference

20 September 2017

Gopal K Potti

3

1 reference

20 September 2017

Bo Peng

4

1 reference

20 September 2017

Thorsten Demberg

5

1 reference

20 September 2017

Luisa Gravlin

6

1 reference

20 September 2017

James Treece

7

1 reference

20 September 2017

Ranajit Pal

8

1 reference

20 September 2017

Eun Mi Lee

9

1 reference

20 September 2017

W Gregory Alvord

10

1 reference

20 September 2017

Phillip D Markham

11

1 reference

20 September 2017

language of work or name

English

0 references

publication date

31 March 2006

1 reference

20 September 2017

1 reference

20 September 2017

24

1 reference

20 September 2017

23

1 reference

20 September 2017

5064-5072

1 reference

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Adenovirus vaccines in the U.S. military

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Role of early region 3 (E3) in pathogenesis of adenovirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Insertion of HIV-1 Genes into Ad4ΔE3 Vector Abrogates Increased Pathogenesis in Cotton Rats Due to E3 Deletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Development of formulations that enhance physical stability of viral vectors for gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Problems associated with the use of live poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Communicability of enteric live adenovirus type 4 vaccine in families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Spread of enteric live adenovirus type 4 vaccine in married couples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4,7, and 21 Vaccines: Safety and Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

7 January 2021

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

7 January 2021

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

7 January 2021

Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.048

7 January 2021

10.1016/J.VACCINE.2006.03.048

Identifiers

DOI

1 reference

20 September 2017

1 reference